-
Digital PET team successfully develops the second generation of "digital PET
Time of Update: 2023-02-02
The new generation of clinical all-digital PET/CT 930 single-bed imaging speed ranks first in the world According to the reporter of Hubei Radio and Television Financial Media, the first PET/CT imported from the United States in Hubei Province was settled in the PET Center of Union Hospital Affiliated to Tongji Medical College of Huazhong University of Science and Technology in 2003.
-
Positive results from Japan's pioneering stem cell transplant trial
Time of Update: 2022-09-10
The first trials to test whether reprogrammed stem cells can repair diseased organs have begun to report positive results .
The first trials to test whether reprogrammed stem cells can repair diseased organs have begun to report positive results .
-
Pharmaceutical biology is still one of the areas that the five major institutions are generally optimistic about and focus
Time of Update: 2022-05-08
16 billion; the net profit attributable to the parent has increased by 210% year-on-year to 930 million yuan .
It is understood that in the first quarter of 2022, Anxu Bio achieved a year-on-year increase of 2763.
-
Baker's yeast and anti-aging therapy
Time of Update: 2022-03-07
"Using current yeast strains, up to 5 tonnes of DLA can be produced per year, and with further optimization, commercial production levels can be reached," explains Yew Wen Shan, Associate Professor, Department of Biochemistry, NUS Faculty of Medicine, and co-principal investigator of the study .
-
[Attention] China Biopharmaceuticals wins ANDA
Time of Update: 2021-03-22
2px;color:#3E3E3E;font-family:;border-width:0px;border-style:none;background-color:#FFFFFF;box-sizing:border-box ;overflow-wrap:break-word ;"> 544px;"> 544px;">March 8,544px;">China Biopharmaceuticals issued an announcement that the drug "Fosapitant Dimeglumine for Injection" (trade name: Shanqi) developed by the group to prevent nausea and vomiting caused by chemotherapy has been approved by the US FDA for a new drug application (ANDA) Application), this is another "three reports and three batches" variety harvested by the group.
-
Sichuan pharmaceutical company wins Novartis's over 2 billion cardiovascular varieties, the original research fails
Time of Update: 2021-03-21
Medical Network News, March 12, March 11, NMPA official website updated the drug approval information, Chengdu Better Pharmaceutical's Valsartan and Amlodipine Tablets (Ⅰ) 4 types of generic listing application was approved, the product is Better The first new product approved for the market this year.
-
Professor Chen Shunle, one of the founders of rheumatology in China, has died
Time of Update: 2021-01-29
Professor Chen Shunle, born in February 1932, is the founder of the rheumatology department of Renji Hospital, affiliated with Shanghai Jiaoxuan University School of Medicine, and the Shanghai Institute of Rheumatology, which has presided over the establishment of China's largest genetic database of the core family of lupus, and the creation of a combination of immunosuppressants to improve efficacy while reducing side effects.
-
What are the characteristics of patent link systems in various countries
Time of Update: 2020-11-29
Unlike the United States, additional registration of patents is not permitted after the drug is on the market, generics do not have a first-in-the-right period, and the proposed infringement is changed to a prohibition order requiring the original pharmaceutical company to apply to the Federal Court for the initiation of a insulation proceeding after receiving notice of the generic drug's application for market listing.
-
New Opportunities: Pharmaceutical Innovation and Investment in the Post-Epidemic Era
Time of Update: 2020-10-11
this year's venture capital conference under the influence of the new crown epidemic can successfully attract many domestic and foreign industry expert leaders to attend, indicating that China's pharmaceutical innovation and development is booming.
-
The first workstations of the Medical Community join hands with the new academic school of Chinese medicine to open a new model of remote service
Time of Update: 2020-07-16
On July 9, 2020, the first batch of work stations of the National Community of New Academic Heritage and Innovation of Chinese Medicine (hereinafter referred to as the Medical Community) signed a form
-
Cell Rep: A new vaccine to stop HIV infection
Time of Update: 2020-06-02
Photo from Cell Reports, 2019, doi: 10.1016/j.celrep.2019.06.074 the researchers first identified a part of the HIV virus that, when combined with antibodies, causes damage to the virus and the cells
-
Review report of CDE chemicals in 2019
Time of Update: 2020-01-06
Original: energy In 2019, the drug dynamic is still one of the important topics related to the national economy and people's livelihood The work of consistency evaluation has been fruitful, and the "4
-
The final list of 2019 "value pioneer" online voting was announced on site on December 28
Time of Update: 2019-11-26
On November 25, under the guidance of China Pharmaceutical Materials Association and sponsored by Sina Pharmaceutical (China) think tank of food and drug industry, the online voting stage of "xinzhihu
-
In the era of meager profit, a large number of generic drugs have been stopped research and development
Time of Update: 2019-10-17
[industry trends of pharmaceutical network] according to public data, as of the end of November 2017, there were 4376 API and preparation manufacturing enterprises in China, of which more than 90% wer
-
"Traditional Chinese Medicine - Banlangen" ISO international standard comes into being to enhance product competitiveness
Time of Update: 2019-02-13
At the time of global influenza, isatis root is one of the most widely used traditional Chinese medicine varieties The international organization for Standardization (ISO) has officially released the
